retatrutide type 2 diabetes phase 2 results 2024 New clinical trial show an investigational Lilly medicine helped adults with significantly lower their A1C (a key measure of blood sugar) and lose weight over 40 weeks. Published Retatrutide vs Survodutide: 24% vs

GLP-1 medicines can help overcome nicotine addiction without side effects (like weight gain) Clinical studies show that GLP-1 medicines reduce the urge to smoke and the rewarding feeling people get from nicotine

Empagliflozin reduced the primary outcome (kidney disease progression or cardiovascular death) by 28% compared with placebo

The social media ads you're seeing are marketing for this actual product

These results translated to significant proportions of participants achieving clinically meaningful weight loss: 5% or More Weight Reduction: 92% (4 mg), 100% (8 mg), 100% (12 mg), and 27% (placebo) 10% or More Weight Reduction: 75% (4 mg), 91% (8 mg), 93% (12 mg), and 9% (placebo) 15% or More Weight Reduction: 60% (4 mg), 75% (8 mg), 83% (12 mg), and 2% (placebo) These data underscore retatrutides potential to deliver unprecedented weight loss in a significant portion of individuals with obesity

Tirzepatide: GI side effects common but well-characterized